A New Question Inside Alcohol Use Disorder Treatment
For decades, the conversation around alcohol use disorder (AUD) has centered on three medications — naltrexone, acamprosate, and disulfiram — alongside therapy, peer support, and structured outpatient care. That conversation is shifting. On May 2, 2026, The Lancet published a randomized, double-blind, placebo-controlled trial showing that once-weekly semaglutide, the GLP-1 receptor agonist already familiar from diabetes and obesity care, significantly reduced heavy drinking days, drinks per drinking day, and self-reported cravings in adults with AUD and comorbid obesity.
For families researching outpatient treatment in San Diego, and for clinicians sending their patients to programs like ours, the question is reasonable: is this a real treatment shift, or another headline that will fade? The honest answer is somewhere in between — and understanding where the evidence actually lands matters more than the press cycle.
What the Lancet Study Actually Found
The trial, led by Anders Fink-Jensen and colleagues, enrolled 108 treatment-seeking adults with AUD and comorbid obesity. Of those, 88 completed the 26-week protocol. Participants received once-weekly injections of either semaglutide or a placebo, alongside standard supportive care.
The published outcomes were notable:
- Heavy drinking days fell significantly more in the semaglutide group than in the placebo group over six months.
- Drinks per drinking day dropped further in the semaglutide arm.
- Self-reported alcohol craving declined more sharply in those receiving semaglutide.
- Markers of harmful alcohol use improved relative to placebo.
What is worth holding alongside that result: every participant had comorbid obesity. The findings cannot yet be generalized to people with AUD at a healthy weight, and they were measured at 26 weeks — not at one, two, or five years. The trial also did not test semaglutide as a standalone treatment. It was layered on top of supportive care, which is how any responsible clinician would prescribe it.
Why GLP-1s Look Different from Earlier AUD Medications
Existing FDA-approved medications for AUD work primarily on opioid receptors (naltrexone), glutamate and GABA systems (acamprosate), or alcohol metabolism (disulfiram). GLP-1 receptor agonists act somewhere else entirely — on reward and satiety circuits in the brain that overlap with addictive behavior. Preclinical work over the last decade in rodent and primate models has consistently shown that GLP-1 activation reduces alcohol-seeking and binge-pattern intake.
That mechanism matters clinically. A person sitting in our intake interview today will sometimes describe their drinking not as a craving for alcohol specifically, but as an inability to stop the loop once it starts — a reward-circuit problem more than a willpower problem. The early GLP-1 data tracks with that description. The drug appears to quiet the loop, not punish the drinker.
What the APA Annual Meeting Added This Week
The American Psychiatric Association’s 2026 Annual Meeting in San Francisco (May 16–20) ran a session on GLP-1 agents in substance use treatment led by Dr. Joji Suzuki. The session reviewed the Fink-Jensen RCT alongside earlier signals from observational studies and the broader pipeline — including a NIH-funded Phase 3 VA trial of semaglutide for AUD that began enrolling on May 1, 2026, with estimated completion in April 2028.
The clinical takeaway from that conversation: GLP-1 agonists are not yet FDA-approved for AUD, and prescribing them off-label for that indication carries the usual considerations around insurance coverage, gastrointestinal side effects, and the need for medical monitoring. But the research base is now strong enough that treating clinicians should know it exists, and patients in outpatient AUD care should be able to ask intelligent questions about whether it might fit their picture.
How This Fits Into Dual Diagnosis Outpatient Treatment
At Refresh Recovery, we treat AUD in the broader context of co-occurring mental health conditions — anxiety, depression, PTSD, bipolar, and trauma-related disorders. The Lancet result does not change the core of that approach. Evidence-based therapy (CBT, DBT, trauma-focused modalities) — see our conditions and modalities for details, medication management, group work, and family involvement remain the foundation of outpatient AUD care.
What it does change is the conversation around medication options. For a person already considering naltrexone, acamprosate, or disulfiram, the emerging GLP-1 data is now part of an honest discussion about evidence, mechanism, and side-effect profile. For a person who has not responded to traditional pharmacotherapy, the new research is reason to revisit the question rather than accept that nothing works.
What this means in practice for our patients
- If you are already in outpatient AUD care, ask your prescriber whether your clinical picture (including weight, metabolic health, and any prior medication response) fits the emerging GLP-1 evidence.
- If you have not started treatment, the new research is not a reason to wait — it is a reason to begin a conversation with a clinician who is actively reading the AUD literature.
- If you tried medication-assisted treatment in the past and stopped, the landscape has shifted. The 2026 evidence base is meaningfully different from what was available even three years ago.
What We Are Watching Next
Three questions will shape AUD treatment in the next 24 months:
- The Phase 3 VA trial (NCT07218354) testing semaglutide in U.S. veterans with AUD — a population where comorbid anxiety, PTSD, and chronic pain often complicate traditional approaches.
- Real-world data on patients already taking GLP-1s for diabetes or obesity who incidentally see reductions in drinking — the largest observational signal so far comes from this group.
- Insurance coverage decisions, which will determine how accessible GLP-1s become for AUD even after the evidence base solidifies.
None of these will move quickly. Phase 3 results are roughly two years out. Coverage discussions usually trail by another year or two beyond that. The honest framing for anyone in active recovery today is that GLP-1s are a credible option in the right clinical picture — not yet a standard of care.
How Refresh Recovery Can Help
Refresh Recovery is a Joint Commission-accredited dual diagnosis outpatient program in San Diego. We treat AUD alongside the mental health conditions that so often co-occur with it. Our clinical team — psychiatrists, licensed therapists, and case managers — actively follows the AUD research landscape and integrates evidence-based pharmacotherapy with CBT, DBT, trauma-focused therapy, group work, and family support.
If you are considering outpatient AUD care, or if the recent research has you reconsidering medication options, the next step is a clinical conversation, not a decision in isolation. Reach out to our admissions team to talk through your situation, your goals — or visit our admissions page, and what evidence-based outpatient treatment in San Diego can look like for you.
